GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

The pharmaceutical company said promising pipeline developments and high demand for drugs in its specialty segment lifted ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Phenotyping children with asthma based on rhinoconjunctivitis symptoms shows that rhinoconjunctivitis may not always be allergy driven.

The 30th Nigerian Economic Summit (#NES30) was held in Abuja on October 14, 2024. At that summit, the Vice President of the ...